Loading
The largest infant leukaemia trial showed that intensifying chemotherapy did not help, and set the stage for adding blinatumomab instead.
651 infants; 6-year EFS 46.1% overall, no benefit from myeloid-style intensification; KMT2A rearrangement (in ~75%) remained the dominant adverse factor. JCO 2019. The follow-on Interfant-21 adds blinatumomab after a pilot (NEJM 2023) showed 2-year DFS 81.6% vs 49.4% historical, and menin inhibitors are entering infant ALL trials.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
651 registered.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival at 6 yearsprimary | All infants | 651 | 46.1% | - | - | link |
Shares Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Acute lymphoblastic leukaemia.
Shares Blinatumomab, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets, Acute lymphoblastic leukaemia.
Shares Blinatumomab, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets, T-cell engagers (bispecific).